Serina Therapeutics, Inc.

Serina Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing wholly owned drug candidates for neurological diseases and other indications. Its core platform, POZ, uses a synthetic poly(2-oxazoline) polymer to modify how drugs are loaded and released, with applications across small molecules, RNA-based therapeutics, and antibody-based drug conjugates.

−18 401,5 %

−14 755,4 %

+132,1 %

1.71

1.71

— Serina Therapeutics, Inc.
%
POZ platform technology20% Synthetic polymer-based formulation technology used to improve drug loading and release control.
Lead clinical candidate SER 25225% A neurological disease program intended for advanced Parkinson’s disease.
Other product candidates35% Wholly owned preclinical and early clinical assets built on the POZ platform.
Research and development services20% Internal discovery, preclinical testing, and clinical development activities.

Serina does not yet sell approved products; its near-term counterparties are regulators, clinical investigators,...

  • Patients with neurological diseasesprimary

    Future end users of approved therapies such as SER 252, especially in Parkinson’s disease and related indications.

  • Physicians and specialty clinicsprimary

    Prescribers who would adopt the therapy if clinical data, safety, and convenience support use.

  • Regulatory agenciesprimary

    FDA and other authorities review INDs, clinical data, and marketing applications that determine whether programs can advance.

  • Pharmaceutical development partnerssecondary

    Potential collaborators or licensees that may fund, develop, or commercialize POZ-enabled candidates.

  • Contract manufacturerssecondary

    CMOs and API suppliers that produce clinical and future commercial material for the pipeline.

Serina is headquartered in the United States and its development, regulatory, and financing activities are centered...

  • •Headquartered in the United States
  • •Clinical and regulatory work is centered in the U.S.
  • •Future commercialization could extend to ex-U.S. markets
  • •Manufacturing may rely on third-party suppliers and CMOs
  • •Geographic exposure is mainly regulatory, not sales-driven today

Serina’s strategy is to advance POZ-enabled drug candidates through preclinical and clinical development, starting with...

01
Advance SER 252 into clinical developmentshort-term

Lead program progress is the main value driver for a clinical-stage biotech.

02
Expand the POZ-enabled pipelinemedium-term

A broader pipeline can diversify scientific risk and create more partnering options.

03
Strengthen manufacturing and regulatory readinessmedium-term

Clinical and future commercial supply depend on reproducible processes and compliant facilities.

04
Maintain financing flexibilityshort-term

Development-stage biotech programs require ongoing external capital before product revenue exists.

Serina faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory delays, and the...

high

Regulatory delay or clinical hold

Drug development depends on FDA acceptance of INDs and trial plans, which can be slowed by data or formulation questions.

Scope
SER 252 and future pipeline programs
Materiality
high
high

Clinical failure or weak efficacy/safety profile

The company’s value depends on demonstrating that POZ-enabled candidates are safe and effective in humans.

Scope
Lead and follow-on programs
Materiality
high
high

Financing and dilution risk

As a pre-revenue biotech, Serina must raise external capital to fund R&D and operations.

Scope
Equity issuance and private placements
Materiality
high
medium

Intellectual property and freedom-to-operate risk

The POZ platform and product candidates rely on patent protection and defense against third-party claims.

Scope
Platform technology and candidate portfolio
Materiality
medium
medium

Manufacturing and supply-chain execution risk

Clinical and future commercial supply depend on third-party manufacturing and reproducible processes.

Scope
API supply, excipients, and CMO relationships
Materiality
medium
Research and development expense recognition
Affects operating loss and comparability across periods
Fair value of warrants and financing instruments
Can distort net income/loss versus cash burn
Stock-based compensation
Affects reported operating expenses and dilution analysis
Going-concern assessment
Signals financing risk and potential future dilution

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

FILANA THERAPEUTICS, INC.

FLNA · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPH · Pharmaceutical Preparations

: 29/04/2026